Imbruvica® (ibrutinib) – Expanded indication
January 28, 2019 - AbbVie announced the FDA approval of Imbruvica (ibrutinib) for use in combination with Gazyva® (obinutuzumab) for adult patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
Download PDF
